Riik: Suurbritannia
keel: inglise
Allikas: MHRA (Medicines & Healthcare Products Regulatory Agency)
Furosemide
Sovereign Medical Ltd
C03CA01
Furosemide
40mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02020200; GTIN: 05021730031107
PACKAGE LEAFLET: INFORMATION FOR THE USER FUROSEMIDE 20 mg and 40 mg Tablets READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. s +EEPTHISLEAFLET9OUMAYNEEDTOREADITAGAIN s )FYOUHAVEANYFURTHERQUESTIONSASKYOURDOCTOROR PHARMACIST s 4HISMEDICINEHASBEENPRESCRIBEDFORYOUONLY$ONOTPASSIT ONTOOTHERS)TMAYHARMTHEMEVENIFTHEIRSIGNSOFILLNESSARE THESAMEASYOURS s )FYOUGETANYSIDEEFFECTSTALKTOYOURDOCTORORPHARMACIST 4HISINCLUDESANYSIDEEFFECTSNOTLISTEDINTHISLEAFLET3EE SECTION WHAT IS IN THIS LEAFLET 7HAT&UROSEMIDE4ABLETSAREANDWHATTHEYAREUSEDFOR 7HATYOUNEEDTOKNOWBEFOREYOUTAKE&UROSEMIDE4ABLETS (OWTOTAKE&UROSEMIDE4ABLETS 0OSSIBLESIDEEFFECTS (OWTOSTORE&UROSEMIDE4ABLETS #ONTENTSOFTHEPACKANDOTHERINFORMATION 1. WHAT FUROSEMIDE TABLETS ARE AND WHAT THEY ARE USED FOR 4HENAMEOFYOURMEDICINEIS&UROSEMIDEMGANDMG 4ABLETSREFERREDTOAS&UROSEMIDE4ABLETSINTHISLEAFLET &UROSEMIDE4ABLETSCONTAINTHEACTIVEINGREDIENTFUROSEMIDE WHICHBELONGSTOAGROUPOFMEDICINESKNOWNASLOOPDIURETICS $IURETICSINCREASETHEAMOUNTOFURINEYOUPRODUCEBYMAKING YOURKIDNEYSALLOWMOREWATERANDSALTSTOBEREMOVEDFROMYOUR BODY &UROSEMIDE4ABLETSAREUSEDTOTREATOEDEMAWHICHISABUILDUP OFFLUIDINTHEBODYTISSUES4HEOEDEMACANBECAUSEDBYHEART ORKIDNEYFAILURELIVERDAMAGEORANOBSTRUCTION)NSOMECASES THEFLUIDMAYBUILDUPINYOURLEGSANDHANDSANDINOTHERCASES INAIRSPACESOFYOURLUNGSPULMONARYOEDEMA &UROSEMIDE 4ABLETSHELPYOURKIDNEYTOREMOVESOMEOFTHEEXCESSFLUIDFROM YOURBODY &UROSEMIDE4ABLETSCANALSOBEUSEDTOTREATMILDTOMODERATE HIGHBLOODPRESSUREEITHERONITSOWNORINCOMBINATIONWITH OTHERDRUGS 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE FUROSEMIDE TABLETS DO NOT TAKE FUROSEMIDE TABLETS s IFYOUAREALLERGICTOFUROSEMIDEORANYOTHERINGREDIENTSOFTHIS MEDICINELISTEDINSECTION s IFYOUHAVESEVEREKIDNEYDAMAGEWHICHHASSTOPPEDTHEM WORKINGPROPERLYANDPRODUCINGURINE s IFYOUHAVEVERYLOWLEVELSOFPOTASSIUMSODIUMOROTHER ELECTROLYTESINYOURBLOODORLOWBLOODVOLUMEYOURDOCTOR WILLBEABLETOADVISEYOU s IFYOUAREDEHYDRATED s IFYOUHAVELOWBLOODPRESSURE s IFYO Lugege kogu dokumenti
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Furosemide 40mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Furosemide 40mg Excipient of known effect Each 40 mg tablet contains 102 mg of lactose. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablets. White circular, flat tablets with bevelled edge, with a breakline and embossed “F/40” on one face. 8mm diameter. The breakline is not intended for breaking the tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS The treatment of oedema associated with congestive heart failure, cirrhosis of the liver, renal disease including nephrotic syndrome and pulmonary oedema. The treatment of peripheral oedema due to mechanical obstruction, venous insufficiency and mild to moderate hypertension (alone, or in combination with other antihypertensive agents in the treatment of more severe cases). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Posology _ _Adults and children over 12 years _ _OEDEMA _ The initial adult dose is 40mg daily, reduced to 20mg daily or 40mg on alternate days. In some patients daily doses of 80mg or higher (given in divided doses) may be required. Maintenance dose is 20 mg daily or 40 mg on alternate days, increased in resistant oedema to 80 mg daily. _ _ _HYPERTENSION _ 20-40mg twice daily; if 40mg twice daily does not lead to a clinically satisfactory response, the addition of other antihypertensive agents, rather than an increase in the dose of furosemide should be considered. _Children under 12 years _ The usual daily dose is 1 to 3mg/kg body weight daily up to a maximum total dose of 40mg/day. _Elderly _ Dosage should be titrated until the required response is achieved because in the elderly furosemide is generally eliminated more slowly. METHOD OF ADMINISTRATION For oral use. _ _ _Dosage adjustment may be required (see also section 4.4)_ Dosage adjustment may be necessary in patients with • hypoproteinaemia • liver congestion/dysfunction _ _ _Concomitant administration Lugege kogu dokumenti